Mediocre Q4 sales for Thoratec's HeartMate LVAD
This article was originally published in Clinica
Executive Summary
Thoratec ended last week on a negative note as its share price fell 8% to close at $9.83 on Friday (December 3), the day after the company forecast flat fourth-quarter sales of its HeartMate XVE left ventricular assist device (LVAD). Implant rates of the product for the first two months of the fourth quarter have been similar to those of the previous quarters in 2004, which ranged between 34 and 42 implants per quarter, according to Thoratec.
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.